GSK, Gilead enter licensing pact to commercialise HB V drug Viread in 5 Asian countries
Thursday, November 26, 2009 10:00 IST London
GlaxoSmithKline (GSK) and Gilead Sciences, Inc announced a licensing agreement to commercialise Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia.